Summary & Overview
CPT 81210: BRAF Mutation Detection, Technical Laboratory Assay
CPT code 81210 represents the technical laboratory assay to detect common mutations in the BRAF gene, a key molecular test in oncology for tumor profiling and therapeutic decision‑making. Nationally, BRAF testing informs targeted therapy choices and diagnostic classification across multiple cancer types, making the code central to cancer molecular diagnostics infrastructure. The analysis covers major national payers and Medicare, reflecting common coverage drivers and billing practices for molecular pathology services. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the clinical context for BRAF testing. The publication summarizes payer coverage themes, common billing modifiers and claim components, and how CPT code 81210 is positioned relative to laboratory technical components in reimbursement workflows. Where available, benchmarking and claim line considerations are outlined to aid coding and billing teams, alongside policy and documentation factors that affect medical necessity determinations. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 81210 describes a laboratory test that detects common changes in the B‑Raf proto‑oncogene, serine/threonine kinase (BRAF) gene. The procedure represents the technical laboratory analysis to identify BRAF variants that are clinically relevant for tumor profiling and targeted therapy selection.
Service Type: Molecular diagnostic testing (technical component)
Typical Site of Service: Clinical laboratory or hospital laboratory (outside the patient‑facing clinical encounter)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a biopsy-confirmed metastatic melanoma is referred for molecular testing to guide targeted therapy. The oncology clinic collects a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides and sends the specimen to a molecular diagnostics laboratory. The laboratory accessioning team verifies specimen identity and clinical indications, then a molecular pathologist orders 81210 to detect common activating variants in the BRAF gene (e.g., V600E). The lab technologist performs DNA extraction, quality assessment, and a validated assay (PCR-based, Sanger sequencing, or next-generation sequencing panel) to detect BRAF mutations. Results are reported to the ordering oncologist and entered into the electronic medical record; positive results can indicate eligibility for BRAF inhibitor therapy, while negative results may prompt broader genomic profiling or alternative treatment planning. Typical sites of service include hospital outpatient laboratories, independent molecular pathology labs, and hospital-based molecular diagnostic services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the interpretation/reporting by the pathologist separate from the technical testing performed by the lab. |